Plain-English translation of NCT06185205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new type of radiation therapy called (APBI) that uses small tubes placed in the breast to deliver radiation directly to the area where the cancer was removed. Instead of weeks of treatment, this approach completes the radiation in just 1.5 days with three short sessions. The goal is to see if this faster treatment is safe and effective for women with early-stage breast cancer.
After breast-conserving surgery, patients typically need several weeks of daily radiation therapy. Researchers want to know if this new treatment can deliver the same radiation dose in a much shorter timeframe, which could be more convenient for patients while maintaining safety and effectiveness.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo a procedure to place small catheters (thin tubes) in your breast in the area where the cancer was removed. Over the next 1.5 days, you will receive three short sessions of radiation therapy through these catheters, then they will be removed. You will also have follow-up visits to monitor your recovery and check for any side effects. The entire treatment course is much faster than traditional radiation, which typically takes 5–6 weeks.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Virginia Commonwealth University
Enrollment target
~170 participants
Started
December 2023
Primary completion
January 2031
Age range
45 Years – 79 Years
Sex
Female only
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Massey IIT Research Operations
Virginia Commonwealth University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.